Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance
With the release of the draft ICH M15 guidance, MIDD is no longer optional -…
Certara2025年6月11日
Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance
SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…
Certara2025年5月23日
Essentials of Model-informed Drug Development in Oncology
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…
Certara2025年5月2日
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…
Certara2025年4月21日
Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy
GRIN Therapeutics, Inc., an affiliate of Neurvati Neurosciences, focuses on the research and development of…
Certara2025年4月16日
Model-informed Formulation Development: Bridging Experimental Data and Mechanistic Modeling
Discover how predictive modeling and model-informed formulation development (MIFD) are accelerating drug development. Learn from…
Certara2025年4月11日
Write Quicker PBPK Reports with the Simcyp Report Assistant
2025年4月11日 Writing a report for PBPK models can be an onerous process, especially…
Certara2025年4月11日
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
RADNOR, PA — April 1st, 2025 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in…
Certara2025年4月1日
PBBM Educational Webinar Series (Part 1): The Basics of Drug Absorption in Drug Development – Why is Drug Absorption Essential? [Japanese Webinar]
Part 2 on July 17th : 薬物吸収モデルとは？Part 3 in…
Certara2025年2月27日
